Hi-Tech Pharmacal Stock Price, News & Analysis (NASDAQ:HITK)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Hi-Tech Pharmacal (NASDAQ:HITK)

Hi-Tech Pharmacal logoHi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.

Receive HITK News and Ratings via Email

Sign-up to receive the latest news and ratings for HITK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Hi-Tech Pharmacal (NASDAQ:HITK) Frequently Asked Questions

What is Hi-Tech Pharmacal's stock symbol?

Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."

Who are some of Hi-Tech Pharmacal's key competitors?

Has Hi-Tech Pharmacal been receiving favorable news coverage?

News articles about HITK stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hi-Tech Pharmacal earned a media sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the healthcare company an impact score of 45.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Hi-Tech Pharmacal?

Shares of HITK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Hi-Tech Pharmacal?

Hi-Tech Pharmacal's mailing address is 369 Bayview Ave, AMITYVILLE, NY 11701-2801, United States. The healthcare company can be reached via phone at +1-516-7898228.

MarketBeat Community Rating for Hi-Tech Pharmacal (HITK)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Hi-Tech Pharmacal and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hi-Tech Pharmacal (NASDAQ:HITK) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Hi-Tech Pharmacal (NASDAQ:HITK) Earnings History and Estimates Chart

Earnings by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)

Hi-Tech Pharmacal (NASDAQ HITK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/11/2014Q314$0.66$0.70$62.35 million$59.90 millionViewN/AView Earnings Details
12/10/2013Q2$0.47$0.71$57.97 million$58.60 millionViewN/AView Earnings Details
9/9/2013Q1 2014$0.44$0.44$57.78 million$50.50 millionViewListenView Earnings Details
7/9/2013Q4 2013$0.63$0.50$66.33 million$58.50 millionViewListenView Earnings Details
3/7/2013Q3 2013$0.71$0.43$60.45 million$64.33 millionViewListenView Earnings Details
12/6/20120.66$0.66$57.54 millionViewListenView Earnings Details
9/5/2012Q113$0.68$0.44$57.60 million$52.00 millionViewN/AView Earnings Details
7/10/2012$0.78$0.73ViewN/AView Earnings Details
3/8/2012$0.87$0.79ViewN/AView Earnings Details
12/5/2011$0.77$1.04ViewN/AView Earnings Details
9/7/2011$0.84$1.05ViewN/AView Earnings Details
7/7/2011$0.71$0.98ViewN/AView Earnings Details
3/10/2011$0.63$0.79ViewN/AView Earnings Details
12/9/2010$0.56$0.76$42.47 million$44.90 millionViewN/AView Earnings Details
9/8/2010Q1 2011$0.51$0.67ViewN/AView Earnings Details
7/13/2010Q4 2010$0.55$0.50ViewN/AView Earnings Details
3/11/2010Q3 2010$0.50$0.67ViewN/AView Earnings Details
12/9/2009Q2 2010$0.32$0.60ViewN/AView Earnings Details
9/9/2009Q1 2010$0.18$0.62ViewN/AView Earnings Details
7/14/2009Q4 2009$0.20$0.42ViewN/AView Earnings Details
3/11/2009Q3 2009$0.19$0.18ViewN/AView Earnings Details
12/9/2008Q2 2009$0.06$0.09ViewN/AView Earnings Details
9/8/2008Q1 2009($0.09)($0.17)ViewN/AView Earnings Details
7/11/2008Q4 2008$0.01$0.02ViewN/AView Earnings Details
3/10/2008Q3 2008$0.03($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Hi-Tech Pharmacal (NASDAQ:HITK) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Hi-Tech Pharmacal (NASDAQ:HITK)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hi-Tech Pharmacal (NASDAQ HITK) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)

Hi-Tech Pharmacal (NASDAQ HITK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2013Gary AprilInsiderSell6,873$43.06$295,951.38View SEC Filing  
10/10/2013Reuben SeltzerChairmanSell11,250$43.13$485,212.50521,510View SEC Filing  
10/8/2013David SeltzerCEOSell23,000$43.09$991,070.001,339,612View SEC Filing  
10/4/2013Martin GoldwynDirectorSell1,500$43.10$64,650.00View SEC Filing  
10/3/2013William J PetersCFOSell21,250$43.11$916,087.50View SEC Filing  
10/2/2013Bruce W SimpsonDirectorSell25,468$43.15$1,098,944.20View SEC Filing  
10/2/2013Reuben SeltzerChairmanSell11,250$43.13$485,212.50View SEC Filing  
2/5/2013William J PetersCFOSell4,639$38.00$176,282.00View SEC Filing  
(Data available from 1/1/2013 forward)


Hi-Tech Pharmacal (NASDAQ HITK) News Headlines

Hi-Tech Pharmaceuticals Forms Joint Venture with Chinese ConglomerateHi-Tech Pharmaceuticals Forms Joint Venture with Chinese Conglomerate
www.prnewswire.com - May 12 at 4:23 AM

SEC Filings

Hi-Tech Pharmacal (NASDAQ:HITK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Hi-Tech Pharmacal (NASDAQ:HITK) Income Statement, Balance Sheet and Cash Flow Statement


Hi-Tech Pharmacal (NASDAQ HITK) Stock Chart for Tuesday, March, 20, 2018

Loading chart…

This page was last updated on 3/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.